We are live on ! Find out more
BCB

Brian C. Broderick Portfolio holdings

AUM $542M
1-Year Est. Return 20.28%
This Fund
S&P 500
This Quarter Est. Return
+11.8%
1 Year Est. Return
+20.28%
3 Year Est. Return
+64.8%
5 Year Est. Return
+86.99%
10 Year Est. Return
+301.53%
AUM
$337M
AUM Growth
+$22.6M
Cap. Flow
-$12.7M
Cap. Flow %
-3.76%
Top 10 Hldgs %
37.59%
Holding
86
New
2
Increased
22
Reduced
37
Closed
9

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$602K
2
NKE icon
Nike
NKE
+$474K
3
TJX icon
TJX Companies
TJX
+$467K
4
BDX icon
Becton Dickinson
BDX
+$337K
5
UNH icon
UnitedHealth
UNH
+$207K

Top Sells

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$3.14M
2
CB icon
Chubb
CB
+$2.12M
3
UNP icon
Union Pacific
UNP
+$1.52M
4
VFC icon
VF Corp
VFC
+$1.44M
5
AAPL icon
Apple
AAPL
+$611K

Sector Composition

Rank Sector Weight
1 Healthcare 22.9%
2 Technology 21.31%
3 Industrials 13.07%
4 Financials 8.44%
5 Consumer Staples 6.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
INTC icon
26
Intel
INTC
$466B
$4.93M 1.46%
98,955
-10,885
-10% -$532K
NVDA icon
27
NVIDIA
NVDA
$5.01T
$4.26M 1.26%
326,280
-10,600
-3% -$142K
CVS icon
28
CVS Health
CVS
$137B
$4.18M 1.24%
61,194
+32
+0.1% +$2.08K
BDX icon
29
Becton Dickinson
BDX
$43.1B
$3.88M 1.15%
15,868
+1,446
+10% +$337K
PEP icon
30
PepsiCo
PEP
$186B
$3.57M 1.06%
24,084
-50
-0.2% -$7.11K
CB icon
31
Chubb
CB
$140B
$3.4M 1.01%
22,105
-15,139
-41% -$2.12M
UNH icon
32
UnitedHealth
UNH
$382B
$3.4M 1.01%
9,691
+618
+7% +$207K
TJX icon
33
TJX Companies
TJX
$170B
$3.31M 0.98%
48,521
+7,675
+19% +$467K
HON icon
34
Honeywell
HON
$77.1B
$3.23M 0.96%
16,112
-154
-0.9% -$28K
CVX icon
35
Chevron
CVX
$388B
$2.45M 0.73%
29,034
-3,254
-10% -$263K
CSCO icon
36
Cisco
CSCO
$450B
$2M 0.59%
44,610
-4,400
-9% -$181K
NKE icon
37
Nike
NKE
$61.9B
$1.9M 0.56%
13,423
+3,576
+36% +$474K
XOM icon
38
ExxonMobil
XOM
$651B
$1.8M 0.54%
43,723
-5,164
-11% -$194K
IRWD icon
39
Ironwood Pharmaceuticals
IRWD
$611M
$1.79M 0.53%
157,100
+55,000
+54% +$602K
ABBV icon
40
AbbVie
ABBV
$458B
$1.73M 0.51%
16,112
SPTM icon
41
State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF
SPTM
$13.5B
$1.62M 0.48%
35,100
UNP icon
42
Union Pacific
UNP
$183B
$946K 0.28%
4,547
-7,635
-63% -$1.52M
MRK icon
43
Merck
MRK
$324B
$862K 0.26%
11,056
-74
-0.7% -$5.66K
BMY icon
44
Bristol-Myers Squibb
BMY
$127B
$726K 0.22%
11,700
KO icon
45
Coca-Cola
KO
$354B
$695K 0.21%
12,680
-600
-5% -$31K
TT icon
46
Trane Technologies
TT
$106B
$645K 0.19%
4,440
-100
-2% -$13.8K
WELL icon
47
Welltower
WELL
$178B
$640K 0.19%
9,910
CHD icon
48
Church & Dwight Co
CHD
$23.1B
$576K 0.17%
6,598
+148
+2% +$13.1K
PBA icon
49
Pembina Pipeline
PBA
$29.9B
$533K 0.16%
22,528
-1,000
-4% -$23.5K
TMO icon
50
Thermo Fisher Scientific
TMO
$211B
$510K 0.15%
1,095

Similar funds

Brian C. Broderick's Q4 2020 Portfolio in Review

As of Q4 2020, Brian C. Broderick held 86 positions worth $337M, up 7.2% from $314M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Brian C. Broderick withdrew a net $12.7M in Q4 2020, closing 9 positions and reducing 37 holdings. Its most notable exit was VF Corp, an estimated $1.44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 23% a quarter earlier, followed by Technology and Industrials.

Against the trend, Brian C. Broderick opened a new position in Ingersoll Rand worth $202K.

  • Brian C. Broderick's largest Q4 2020 buy was Ingersoll Rand: 4,435 shares worth $202K.
  • Brian C. Broderick added most to Ironwood Pharmaceuticals in Q4 2020, an estimated $602K increase.
  • Brian C. Broderick's biggest Q4 2020 reduction was Denali Therapeutics, cutting an estimated $3.14M.
  • Brian C. Broderick fully exited VF Corp in Q4 2020, selling an estimated $1.44M.
  • Brian C. Broderick's ten largest holdings make up 38% of its $337M portfolio in Q4 2020.
  • Brian C. Broderick opened 2 new positions and closed 9 in Q4 2020.
  • Brian C. Broderick's portfolio value rose 7.2% quarter-over-quarter to $337M.

Based on Brian C. Broderick's 13F filing for Q4 2020, filed 16 Feb 2021.